CFO Research Results 2019

Findings from Criticaleye's CFO Retreat Research:

  • 71% of CFOs report that stakeholder engagement is becoming more complex and difficult
  • Only 8% are fully confident the senior team can respond to business model disruption
  • 96% of CFOs say their top team is too inward-looking and focused on the short-term
  • 64% say the Chair does not add value in terms of supporting the executive team
  • Building alignment in the senior team is where CFOs say they are falling short

Click here to watch Phil Smith, Chair, Innovate UK (& Criticaleye Board Mentor); Dame Alison Carnwath, Non-executive Director, BP; Vindi Banga, Senior Independent Director, GSK; Mike Evans, Chair, Just Eat; and Tony Hayward, Chair, Glencore share their views on where the CFO is adding value. 




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
The Boards' Cyber-Risk Compas...

In this insight, Criticaleye Retreat Partner Palo Alto Networks shares the 10 questions every director should ask to govern, fortify and strategise their organisation’s approach to cyber risk.

Click here to download this insight
The Price of Paralysis

Criticaleye lead Partner AlixPartners paints a stark picture of global volatility, economic fragility, geopolitical shocks and relentless market shifts, in its 2025 'Turnaround and Transformation...

Click here to download this insight
Practical AI for CEOs

AlixPartners’ Practical AI for CEOs playbook cuts through the hype to show how leaders can turn AI ambition into measurable business value. In a market defined by rapid innovation and intensifying competition, the...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 450




Rolls-Royce Google Drax Group plc NatWest Group Concentrix Lightsource bp Hitachi Solutions E.ON UK Accenture AlixPartners Legal & General Workday Salesforce London Stock Exchange Group Aldermore Group Worldpay NATS British Land IBM Consulting Eightfold AI FTSE Women Leaders Review Palo Alto Networks GlaxoSmithKline plc